Protecting the thymic epithelial cells and thymopoiesis during hematopoietic stem cell transplantation

ProtecTHY aims to uncover the protective mechanisms of the human thymus during alloHSCT to prevent thymic damage and improve outcomes through innovative research and clinical treatment assessment.

Subsidie
€ 2.175.054
2025

Projectdetails

Introduction

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a common, often last-resort treatment for haematological diseases, but it is plagued by long-term morbidity and high mortality. Direct alloHSCT-induced damage to the thymus and subsequent loss of thymopoiesis, i.e., the production of new T cells, is considered one of the main reasons for these complications.

Background

Our limited understanding of how the thymus is damaged during alloHSCT restricts the development of thymus-protecting protocols. The goal of ProtecTHY is to unravel the intrinsic protective mechanisms of the human thymus and assess how alloHSCT affects them, with the ultimate objective of devising measures to prevent thymic damage.

Methodology

We take advantage of an innovative whole organ culture system for the human thymus developed in my laboratory and our extensive pre-existing collection of human thymus tissue samples spanning a diverse age range. ProtecTHY specifically aims to:

  1. Discover how the thymus protects itself from external insults over the course of the human lifetime.
  2. Reveal how alloHSCT disrupts the human thymus microanatomy and how that damage can be prevented with a cellular therapy.
  3. Examine how thymic damage affects the circulating true naive T cells and if existing clinical treatments for alloHSCT complications can restore the loss of thymopoiesis.

Techniques

We will apply state-of-the-art spatial and single-cell multiomics to dissect these protective layers of the thymus both ex vivo and after alloreactive challenge in vitro. Moreover, by testing the effect of treatments already in clinical use, ProtecTHY can resolve their specific mechanisms of action and impact on the thymus.

Impact

Our results are thus directly translatable to the human condition and can direct future treatments to enhance outcomes following alloHSCT. As a translational immunologist and clinical microbiologist with extensive experience in human thymus research, I am well equipped to uncover the mechanisms of thymic protection.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.175.054
Totale projectbegroting€ 2.175.054

Tijdlijn

Startdatum1-1-2025
Einddatum31-12-2029
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • HELSINGIN YLIOPISTOpenvoerder

Land(en)

Finland

Vergelijkbare projecten binnen European Research Council

ERC Starting...

How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantation

RESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes.

€ 1.500.000
ERC Consolid...

MICROBOTS – Unravel the power of MICRObial metaBOliTeS to prevent graft versus host disease and cure leukemia relapse

The "MICROBOTS" project aims to characterize gut microbiome signatures in allo-SCT patients to enhance antitumor responses and reduce GVHD through precision fecal microbiota transplantation.

€ 1.999.901
ERC Advanced...

Deciphering cellular signalling to cure graft-versus-host disease (GVHD) and leukemia relapse

AlloCure aims to identify and target pathogenic signaling in immune and leukemia cells to develop personalized therapies that reduce mortality from GVHD and leukemia relapse post-allo-HCT.

€ 2.498.943
ERC Consolid...

TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION

FUN-HSC aims to identify and mimic maturation pathways of hematopoietic stem cells from pluripotent stem cells to create a reliable, clinically valuable source for diverse therapies.

€ 2.265.684
ERC Proof of...

Preventing rejection and ensuring survival of grafts

This project aims to enhance organ transplant success by using Listeria monocytogenes to protect grafted cells from T-cell killing, reducing reliance on immunosuppressive drugs and improving patient outcomes.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system

i-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028.

€ 2.495.510
EIC Pathfinder

Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application

This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.

€ 3.797.562
EIC Transition

Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia

The project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes.

€ 2.497.500
EIC Pathfinder

building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans

THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.

€ 3.994.150
EIC Pathfinder

Bottom-up manufacturing of artificial anti-tumor T cells

The project aims to develop Artificial T cells (ArTCells) that mimic T cell therapy's anti-tumor functions more safely and cost-effectively, using engineered Giant Unilamellar Vesicles for targeted cancer treatment.

€ 3.391.796